Celecoxib Promotes c-FLIP Degradation through Akt-Independent Inhibition of GSK3
Open Access
- 29 September 2011
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 71 (19), 6270-6281
- https://doi.org/10.1158/0008-5472.can-11-0838
Abstract
Celecoxib is a COX-2 inhibitor that reduces the risk of colon cancer. However, the basis for its cancer chemopreventive activity is not fully understood. In this study, we defined a mechanism of celecoxib action based on degradation of cellular FLICE-inhibitory protein (c-FLIP), a major regulator of the death receptor pathway of apoptosis. c-FLIP protein levels are regulated by ubiquitination and proteasome-mediated degradation. We found that celecoxib controlled c-FLIP ubiquitination through Akt-independent inhibition of glycogen synthase kinase-3 (GSK3), itself a candidate therapeutic target of interest in colon cancer. Celecoxib increased the levels of phosphorylated GSK3, including the α and β forms, even in cell lines, where phosphorylated Akt levels were not increased. Phosphoinositide 3-kinase inhibitors abrogated Akt phosphorylation as expected but had no effect on celecoxib-induced GSK3 phosphorylation. In contrast, protein kinase C (PKC) inhibitors abolished celecoxib-induced GSK3 phosphorylation, implying that celecoxib influenced GSK3 phosphorylation through a mechanism that relied upon PKC and not Akt. GSK3 blockade either by siRNA or kinase inhibitors was sufficient to attenuate c-FLIP levels. Combining celecoxib with GSK3 inhibition enhanced attenuation of c-FLIP and increased apoptosis. Proteasome inhibitor MG132 reversed the effects of GSK3 inhibition and increased c-FLIP ubiquitination, confirming that c-FLIP attenuation was mediated by proteasomal turnover as expected. Our findings reveal a novel mechanism through which the regulatory effects of c-FLIP on death receptor signaling are controlled by GSK3, which celecoxib acts at an upstream level to control independently of Akt. Cancer Res; 71(19); 6270–81. ©2011 AACR.Keywords
Other Versions
This publication has 48 references indexed in Scilit:
- Identification of an antiapoptotic protein complex at death receptorsCell Death & Differentiation, 2008
- The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor–induced apoptosisMolecular Cancer Therapeutics, 2008
- Targeting the protein kinase C family: are we there yet?Nature Reviews Cancer, 2007
- S6K1 Regulates GSK3 under Conditions of mTOR-Dependent Feedback Inhibition of AktMolecular Cell, 2006
- Neurotensin Phosphorylates GSK-3α/β through the Activation of PKC in Human Colon Cancer CellsNeoplasia, 2006
- Glycogen Synthase Kinase-3 (GSK3): Inflammation, Diseases, and TherapeuticsNeurochemical Research, 2006
- The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathwaysProgress in Neurobiology, 2006
- Exploiting the PI3K/AKT Pathway for Cancer Drug DiscoveryNature Reviews Drug Discovery, 2005
- Phosphorylation of glycogen synthase kinase-3β at serine-9 by phospholipase Cγ1 through protein kinase C in rat 3Y1 fibroblastsExperimental & Molecular Medicine, 2002
- Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cellsOncogene, 1999